PriceTargets.com logo

Werewolf Therapeutics - HOWL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.58
  • Forecasted Upside: 314.71%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.55 As of 12/1/2023 01:00 AM ET
▲ +0.1 (4.08%)

This chart shows the closing price for HOWL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Werewolf Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOWL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOWL

Analyst Price Target is $10.58
▲ +314.71% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Werewolf Therapeutics in the last 3 months. The average price target is $10.58, with a high forecast of $15.00 and a low forecast of $8.30. The average price target represents a 314.71% upside from the last price of $2.55.

This chart shows the closing price for HOWL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Werewolf Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
10/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
9/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
8/23/2023WedbushInitiated CoverageOutperform$9.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
5/12/2023Bank of AmericaBoost Target$9.00 ➝ $10.00Low
3/24/2023EF Hutton Acquisition Co. IReiterated RatingBuy$8.30Low
3/23/2023HC WainwrightLower TargetBuy$20.00 ➝ $15.00Low
2/27/2023EF Hutton Acquisition Co. IReiterated RatingBuy$8.30Low
2/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$8.30Low
12/5/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$8.30Low
6/2/2022HC WainwrightReiterated RatingBuy$20.00High
11/19/2021SVB LeerinkLower TargetOutperform$29.00 ➝ $28.00Medium
11/1/2021HC WainwrightReiterated RatingBuy$32.00Medium
9/14/2021HC WainwrightReiterated RatingBuy$32.00High
9/10/2021Bank of AmericaInitiated CoverageBuy$26.00High
8/17/2021Evercore ISIReiterated RatingBuy$23.00High
5/25/2021SVB LeerinkInitiated CoverageOutperform$29.00High
5/25/2021Evercore ISIInitiated CoverageOutperform$23.00High
5/25/2021Jefferies Financial GroupInitiated CoverageBuy$22.00High
5/25/2021HC WainwrightInitiated CoverageBuy$32.00High
(Data available from 12/3/2018 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
Mentions as of
5/7/2023
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/6/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/6/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/4/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2023

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Werewolf Therapeutics logo
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $2.55
Low: $2.38
High: $2.57

50 Day Range

MA: $2.30
Low: $1.78
High: $3.17

52 Week Range

Now: $2.55
Low: $1.39
High: $4.57

Volume

91,433 shs

Average Volume

2,368,221 shs

Market Capitalization

$92.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Werewolf Therapeutics?

The following Wall Street sell-side analysts have issued reports on Werewolf Therapeutics in the last year: Bank of America Co., EF Hutton Acquisition Co. I, HC Wainwright, and Wedbush.
View the latest analyst ratings for HOWL.

What is the current price target for Werewolf Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Werewolf Therapeutics in the last year. Their average twelve-month price target is $10.58, suggesting a possible upside of 314.7%. HC Wainwright has the highest price target set, predicting HOWL will reach $15.00 in the next twelve months. EF Hutton Acquisition Co. I has the lowest price target set, forecasting a price of $8.30 for Werewolf Therapeutics in the next year.
View the latest price targets for HOWL.

What is the current consensus analyst rating for Werewolf Therapeutics?

Werewolf Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOWL will outperform the market and that investors should add to their positions of Werewolf Therapeutics.
View the latest ratings for HOWL.

What other companies compete with Werewolf Therapeutics?

Other companies that are similar to Werewolf Therapeutics include CytomX Therapeutics, MediciNova, Capricor Therapeutics, Longboard Pharmaceuticals and Reviva Pharmaceuticals. Learn More about companies similar to Werewolf Therapeutics.

How do I contact Werewolf Therapeutics' investor relations team?

Werewolf Therapeutics' physical mailing address is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. The company's listed phone number is 617-952-0555 and its investor relations email address is [email protected]. The official website for Werewolf Therapeutics is werewolftx.com. Learn More about contacing Werewolf Therapeutics investor relations.